Anika Therapeutics (ANIK) EBIT (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of EBIT data on file, last reported at -$5.5 million in Q1 2026.

• EBIT for Q1 2026 came in at -$5.5 million, down 28.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.3 million (down 78.12% YoY), and the FY2025 annual result was -$11.1 million, down 116.64% from the prior year.
• EBIT fell to -$5.5 million in Q1 2026 per ANIK's latest filing, from $646000.0 in the prior quarter.
• Over five years, EBIT peaked at $24.7 million in Q4 2023 and troughed at -$12.6 million in Q1 2023.
• A 5-year average of -$1.0 million and a median of -$3.4 million in 2022 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2025: EBIT soared 279.8% in 2022, then plunged 3891.36% in 2025.
• A 5-year view of EBIT shows it stood at $16.4 million in 2022, then jumped by 50.59% to $24.7 million in 2023, then sank by 102.85% to -$705000.0 in 2024, then jumped by 191.63% to $646000.0 in 2025, then sank by 949.54% to -$5.5 million in 2026.
• Business Quant data shows ANIK's EBIT at -$5.5 million in Q1 2026, $646000.0 in Q4 2025, and -$3.2 million in Q3 2025.